tbuckley/cabot-search huggingface dataset:
People living with HIV in Estonia: engagement in HIV care in 2013
Authors: Kaja-Triin Laisaar, Mait Raag, Irja Lutsar, Anneli Uusküla
Journal: Eurosurveillance (2016)

Estonia had the highest rate of newly diagnosed human immunodeficiency virus (HIV) cases in the European Union (24.6/100,000) and an estimated adult HIV prevalence of 1.3% in 2013. HIV medical care, including antiretroviral therapy (ART), is free of charge for people living with HIV (PLHIV). To maximise the health benefits of HIV treatment, universal access should be achieved. Using data from surveillance and administrative databases and the treatment cascade model, we assessed the number of people infected with HIV, diagnosed with HIV, linked to HIV care, retained in HIV care, on ART, and with suppressed viral load (HIV-RNA: &lt; 200 copies/mL). We identified that about one quarter of the 8,628 HIV-positive people estimated to live in Estonia in 2013 had not been diagnosed with HIV, and another quarter, although aware of their HIV-positive serostatus, had not accessed HIV medical care. Although altogether only 12–15% of all PLHIV in Estonia had achieved viral suppression, the main gap in HIV care in Estonia were the 58% of PLHIV who had accessed HIV medical care at least once after diagnosis but were not retained in care in 2013.
Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study
Authors: Cyriac Abby Philips, Apurva Pande, S. Murali Shasthry, Kapil Dev Jamwal, Vikas Khillan, Shivendra Singh Chandel, Guresh Kumar, Manoj K. Sharma, Rakhi Maiwall, Ankur Jindal, Ashok Choudhary, Md Shabbir Hussain, Shvetank Sharma, Shiv K. Sarin
Journal: Clinical Gastroenterology and Hepatology (2016)
A Phase II Trial of Gleevec™ in Patients with Refractory/Relapsed Myeloma.
Authors: Angela Dispenzieri, Thomas E. Witzig, Martha Q. Lacy, Susan M. Geyer, Teresa Kimlinger, S. Vincent Rajkumar, Philip R. Greipp, Rafael Fonseca, John A. Lust, Steven R. Zeldenrust, Susazanne R. Hayman, Morie A. Gertz
Journal: Blood (2004)
Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Authors: Alexander Drilon, Natasha Rekhtman, Maria Arcila, Lu Wang, Andy Ni, Melanie Albano, Martine Van Voorthuysen, Romel Somwar, Roger S Smith, Joseph Montecalvo, Andrew Plodkowski, Michelle S Ginsberg, Gregory J Riely, Charles M Rudin, Marc Ladanyi, Mark G Kris
Journal: The Lancet Oncology (2016)
Identification of Two Heritable Cross-Disorder Endophenotypes for Tourette Syndrome
Authors: Sabrina M. Darrow, Matthew E. Hirschtritt, Lea K. Davis, Cornelia Illmann, Lisa Osiecki, Marco Grados, Paul Sandor, Yves Dion, Robert King, David Pauls, Cathy L. Budman, Danielle C. Cath, Erica Greenberg, Gholson J. Lyon, Dongmei Yu, Lauren M. McGrath, William M. McMahon, Paul C. Lee, Kevin L. Delucchi, Jeremiah M. Scharf, Carol A. Mathews
Journal: American Journal of Psychiatry (2016)

Phenotypic heterogeneity in Tourette syndrome is partly due to complex genetic relationships among Tourette syndrome, obsessive-compulsive disorder (OCD), and attention deficit hyperactivity disorder (ADHD). Identifying symptom-based endophenotypes across diagnoses may aid gene-finding efforts.Assessments for Tourette syndrome, OCD, and ADHD symptoms were conducted in a discovery sample of 3,494 individuals recruited for genetic studies. Symptom-level factor and latent class analyses were conducted in Tourette syndrome families and replicated in an independent sample of 882 individuals. Classes were characterized by comorbidity rates and proportion of parents included. Heritability and polygenic load associated with Tourette syndrome, OCD, and ADHD were estimated.The authors identified two cross-disorder symptom-based phenotypes across analyses: symmetry (symmetry, evening up, checking obsessions; ordering, arranging, counting, writing-rewriting compulsions, repetitive writing tics) and disinhibition (uttering syllables/words, echolalia/palilalia, coprolalia/copropraxia, and obsessive urges to offend/mutilate/be destructive). Heritability estimates for both endophenotypes were high and statistically significant (disinhibition factor=0.35, SE=0.03; symmetry factor=0.39, SE=0.03; symmetry class=0.38, SE=0.10). Mothers of Tourette syndrome probands had high rates of symmetry (49%) but not disinhibition (5%). Polygenic risk scores derived from a Tourette syndrome genome-wide association study (GWAS) were significantly associated with symmetry, while risk scores derived from an OCD GWAS were not. OCD polygenic risk scores were significantly associated with disinhibition, while Tourette syndrome and ADHD risk scores were not.The analyses identified two heritable endophenotypes related to Tourette syndrome that cross traditional diagnostic boundaries. The symmetry phenotype correlated with Tourette syndrome polygenic load and was present in otherwise Tourette-unaffected mothers, suggesting that this phenotype may reflect additional Tourette syndrome (rather than OCD) genetic liability that is not captured by traditional DSM-based diagnoses.
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
Authors: Mark A Boyd, Janaki Amin, Patrick W G Mallon, Nagalingeswaran Kumarasamy, Johan Lombaard, Robin Wood, Ploenchan Chetchotisakd, Praphan Phanuphak, Lerato Mohapi, Iskandar Azwa, Waldo H Belloso, Jean-Michel Molina, Jennifer Hoy, Cecilia L Moore, Sean Emery, David A Cooper
Journal: The Lancet HIV (2016)
β2-Glycoprotein 1 Antibodies Directly Activate the Platelet IgG Receptor, FcγRIIa, and Cause Thrombosis in FCGR2A Transgenic but Not in Wild Type Mice
Authors: Ali Amirkhosravi, Todd V Meyer, Liza Robles-Carrillo, Meghan Hatfield, Hina Desai, Mildred Amaya, Florian Langer, Steven E. McKenzie, John L Francis
Journal: Blood (2012)
The Role of Donor Lymphocyte Infusion (DLI) and Imatinib Mesylate in the Treatment of Relapse after Allogenic Stem Cell Transplant for Chronic Myeloid Leukemia.
Authors: Mammen Chandy, Uday Deotare, Biju George, Vikram Mathews, Auro Viswabandya, Ashish Bajel, Alok Srivastava
Journal: Blood (2005)
Natural Killer (NK) or NK/T Cell Lineage Large Granular Lymphocytosis Associated with Dasatinib Therapy for Philadelphia Chromosome Positive Leukemia.
Authors: Dong Hwan Kim, Suzanne Kamel-Reid, Hong Chang, Robert Sutherland, Chul Won Jung, Hyeoung Joon Kim, Je-Jung Lee, Jeffrey H. Lipton
Journal: Blood (2008)
Derivative (1) t(1;1) (p36; q21) Produces the Fusion Protein with Phosphatase 10 and MEL1 (MDS1/EVI1-Like Gene 1) in a AML (M5a) Case.
Authors: Mitsuho Noguchi, Haruko Tashiro, Ryosuke Shirasaki, Moritaka Goto, Kazuo Kawasugi, Naoki Shirafuji
Journal: Blood (2005)
Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study.
Authors: Guido Finazzi, Elisa Rumi, Alessandro M. Vannucchi, Maria Luigia Randi, Ilaria Nichele, Heinz Gisslinger, Rakhee Vaidya, Mario Cazzola, Alessandro Rambaldi, Lisa Pieri, Francesco Rodeghiero, Animesh Pardanani, Juergen Thiele, Francesco Passamonti, T Barbui, Ayalew Tefferi
Journal: Blood (2012)
Over a third of children aged 10-11 in England are overweight or obese
Authors: Susan Mayor
Journal: BMJ (2016)

More than a third of children aged 10-11 are overweight or obese, national figures in England have shown.1 Child health experts now describe the level of childhood obesity in the United Kingdom as a “state of emergency.”

The figures for 2015-16 come from the national child measurement programme, which measures height and weight in more than a million children in reception class (aged 4-5) and in year six (aged 10-11) in schools in England each year.

The latest measurements showed that the prevalence of obesity in year six children had increased from 19.1% …
Double Umbilical Cord Blood Transplantation Preceded by a Reduced-Intensity Conditioning Regimen: Rapid Induction of Single Donor Chimerism and Highly Predictive Value of Early CD4+ T Cell and NK Cell Predominance
Authors: Judith AE Somers, Anneke Brand, Bronno van der Holt, Yvette van Hensbergen, Kees Sintnicolaas, Machteld Oudshoorn, Arend Mulder, Eric Braakman, Cynthia Huisman, Jeroen JWM Janssen, Erik WAF Marijt, Eefke J Petersen, Marlies Groenendijk-Sijnke, Jan J Cornelissen
Journal: Blood (2011)
CBM-05FUNCTIONAL DIFFERENCES BETWEEN PD-1<sup>+</sup>AND PD-1<sup>–</sup>CD4<sup>+</sup>T EFFECTOR CELLS IN HEALTHY DONORS AND PATIENTS WITH GLIOBLASTOMA
Authors: Brittany A. Goods, Daniel E. Lowther, Liliana Lucca, Amanda Hernandez, Benjamin Lerner, Murat Gunel, Khadir Raddassi, Jason Simon, Vlad Coric, J. Christopher Love, David A. Hafler
Journal: Neuro-Oncology (2015)

BACKGROUND: The PD-1/PD-L1 immunomodulatory pathway plays a central role in regulating T-cell effector function and has been implicated in immune evasion in glioblastoma. It is also known that populations of tumor-infiltrating lymphocytes may be responsible for disease progression and poor prognosis. A substantial number of these lymphocytes are T effector cells (CD4+CD25−CD127+), however little is known about their function in the tumor microenvironment in glioblastoma or their expression of PD-1. METHODS: We characterized functional differences between T effector cells derived from blood and tumors of patients with glioblastoma (n = 20), with the hypothesis that PD-1 would mark a dysfunctional T effector population. T effector cell proliferative capacity was assessed by stimulation with anti-CD3/anti-CD28/anti-CD2 in thymidine incorporation assays; cytokine production profiles were assessed ex vivo by stimulation with PMA and ionomycin; transcriptional profiling was determined by RNA sequencing. We also performed transcriptional profiling on PD-1+ and PD-1− T effector subsets isolated from the peripheral blood and tumors of patients with glioblastoma and from the peripheral blood of healthy donors. RESULTS: The frequency of PD-1+TIM-3+ T effectors in the peripheral blood of patients with glioblastoma was significantly increased compared to healthy controls. Tumor-derived PD-1+ T effectors displayed significantly less proliferation but retained the ability to produce inflammatory cytokines, including IFNγ. PD-1+ T effectors derived from healthy donors displayed impaired proliferation, which could not be rescued by PD-1/PD-L1 blockade or the addition of IL-2. PD-1+ T effector cells were enriched in several gene sets, indicating that PD-1+ T effector cells may be clonally exhausted. We also identified several genes that differentiated tumor-derived and peripheral blood-derived PD-1+ T effectors in glioblastoma patients. CONCLUSIONS: These data indicate that PD-1 expression marks a dysfunctional population of clonally exhausted T effector cells that may be important in the context of glioblastoma.
Prognostic Value of Serum Ferritin, Transferrin Saturation and C- Reactive Protein At Diagnosis In Myelodysplastic Syndrome Patients: Analysis of Patients From the MDS Piedmont Registry,
Authors: Emanuela Messa, Daniela Gioia, Claudia Bertassello, Gianni Ciccone, Andrea Evangelista, Ceccarelli Manuela, Bernardino Allione, Daniela Cilloni, Flavia Salvi, Gianni Cametti, Monia Lunghi, Dario Ferrero, Patrizia Falco, Margherita Bonferroni, Giuseppe Saglio, Alessandro Levis
Journal: Blood (2011)
Impact of Red Blood Cell and Platelet Transfusions in Acute Myeloid Leukemia (AML) Patients Undergoing Remission Induction Chemotherapy
Authors: Christopher Pleyer, Amber Afzal, William Shomali, Paul Elson, Jia Xuefei, Suzanne Bakdash, Anjali S. Advani, Aaron T. Gerds, Hetty E. Carraway, Matt Kalaycio, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2015)
ATCT-34BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB PLUS VORINOSTAT VERSUS BEVACIZUMAB ALONE IN ADULTS WITH RECURRENT GLIOBLASTOMA
Authors: Jing Wu, Vinay K. Puduvalli, Ying Yuan, Terri Armstrong, Brenda Walker, Charlene Upshaw, Pierre Giglio, Howard Colman, Morris D. Groves, Jeffrey Raizer, Tobias Walbert, David Tran, Nicholas Avgeropoulos, Fabio Iwamoto, David Peereboom, Marc Chamberlain, Ryan Merrell, Nina Paleologos, Karen Fink, Mark R. Gilbert
Journal: Neuro-Oncology (2015)

BACKGROUND: Antiangiogenic therapy using bevacizumab (Bev) has shown promising activity against recurrent glioblastoma. However, the resistance to such treatment often results in aggressive tumor recurrence. Histone deacetylase (HDAC) inhibitors such as vorinostat (Vor) have pleotropic effects against several pathways that may mitigate resistance mechanism. METHODS: A phase II multicenter clinical trial was conducted using Bayesian adaptive design, which allows the randomization to favor the better-performing treatment arm. Patients with recurrent glioblastoma were randomized to receive Bev alone or Bev + Vor. Primary endpoint was progression-free survival (PFS), while overall survival (OS) and patient-reported symptoms using the M.D. Anderson Symptom Inventory-Brain Tumor (MDASI-BT) were secondary end points. Eligible patients were adults with histologically confirmed glioblastoma who had recurrent disease after radiation and temozolomide therapy, KPS ≥ 60, no prior Bev or HDAC inhibitors. RESULTS: Ninety patients (Bev + Vor: 49, Bev: 41) were enrolled to the study. Seventy-three patients were evaluable for the primary endpoint (Bev + Vor: 43, Bev: 30). There were no significant differences between the two arms in either median PFS (4.0 vs.3.7 months, p = 0.90) or median OS (9.2 vs. 7.9 months, p = 0.75). Analysis of the MDASI-BT scores showed no significant differences in overall symptom burden or interference (p = 0.48, 0.71 respectively). Fifty-seven patients were deceased by the time of analysis (Bev + Vor: 34, Bev: 23) with one possible treatment-related death due to pulmonary embolism. Toxicity ≥ grade 3 included hypertension (n = 37), neurological changes (n = 2), infections (n = 9), wound dehiscence (n = 2), DVT/PE (n = 2), and colonic perforation (n = 1). CONCLUSIONS: In this trial, Bev + Vor neither improved PFS and OS nor reduced symptom burden compared to Bev alone in patients with recurrent glioblastoma. However, the successful completion of this Bayesian designed study confirmed the feasibility of conducting an adaptive randomized clinical trial in a multicenter setting.
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme
Authors: Dragana Bugarski-Kirola, Nakao Iwata, Snjezana Sameljak, Carol Reid, Thomas Blaettler, Laurie Millar, Tiago Reis Marques, George Garibaldi, Shitij Kapur
Journal: The Lancet Psychiatry (2016)
Therapy with Imatinib In Elderly CML Patients (&gt;65years): Results of the German CML-Study IV.
Authors: Susanne Saussele, Nadine Pletsch, Michael Lauseker, Armin Leitner, Susanne Jung-Munkwitz, Ulrike Proetel, Martin C. Müller, Claudia Haferlach, Brigitte Schlegelberger, Gerhard Ehninger, Dieter K. Hossfeld, Stefan W. Krause, Christoph Nerl, Hans Pralle, Dominik Heim, Gabriela M. Baerlocher, Leopold Balleisen, Hermann Einsele, Anthony D. Ho, Christiane Falge, Matthias Hänel, M. Pfreundschuh, Lothar Kanz, Frank Stegelmann, Claus-Henning Köhne, Stephan Kremers, Karsten Spiekermann, Steffen Koschmieder, Cornelius F. Waller, Martin Bentz, Markus Pfirrmann, Andreas Hochhaus, Jörg Hasford, Rüdiger Hehlmann, for The German CML-Study Group
Journal: Blood (2010)
Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.
Authors: Ian W. Flinn, Elizabeth Kumm, Michael R. Grever, Donna Neuberg, Gordon W. Dewald, John M. Bennett, Elisabeth M. Paietta, Mohamad A. Hussein, Dennis F. Moore, Martin S. Tallman
Journal: Blood (2004)
Randomized Phase II Study of Proteinase 3-Derived PR1 Peptide Vaccine and GM-CSF with or without PEG-Interferon ALFA-2B to Eradicate Minimal Residual Disease in Chronic Myeloid Leukemia
Authors: Alfonso QuintásCardama, Hagop M. Kantarjian, Rosa Rios, Eric D. Wieder, Jeffrey J. Molldrem, Jorge Cortes
Journal: Blood (2008)
PDE4 Differential Expression Is a Potential Prognostic Factor and a Therapeutic Target in Myelodysplastic Syndromes
Authors: Ali N. Chamseddine, Yue Wei, Monica Cabrero, Irene Ganan-Gomez, Simona Colla, Koichi Takahashi, Hui Yang, Marcos R Estecio, Zachary S. Bohannan, Sherry Pierce, Carlos E. Bueso-Ramos, Hagop M Kantarjian, Elias Jabbour, Guillermo Garcia-Manero
Journal: Blood (2015)
Outpatient-Based Therapy with Oral Fludarabine and Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Authors: William Hwang, C. Dearden, S.M. Loh, Y.C. Linn, S.L. Tien, G. Teoh, L.F. Lim, P.X. Liew, G.F. How, K.K. Heng, Y.T. Goh, L.H. Lee
Journal: Blood (2006)
Outcomes Of Allogeneic Blood Or Marrow Transplantation (AlloBMT) In Multiple Myeloma With Post-Transplantation Cyclophosphamide (PTCy)
Authors: Nilanjan Ghosh, Xiaobu Ye, Javier Bolaños-Meade, Ephraim J. Fuchs, Leo Luznik, Jennifer A. Kanakry, Robert A. Brodsky, Mark Levis, Lode J. Swinnen, Douglas Gladstone, Yvette L. Kasamon, Richard F. Ambinder, Richard J. Jones, William Matsui, Ivan M. Borrello, Carol Ann Huff
Journal: Blood (2013)
Gene Expression Profiling of Sorted Peripheral Blood Cells Using Microarray and Next Generation Sequencing Reveals Distinct Molecular Signatures in the Polymorphonuclear and Mononuclear Cells of Patients with Polycythemia Vera and Primary Myelofibrosis
Authors: Chieh Lee Wong, Baoshan Ma, Gareth Gerrard, Martyna Adamowicz-Brice, Zainul Abidin Norziha, Nor Rafeah Tumian, Soon Keng Cheong, Chooi Fun Leong, Ping Chong Bee, Gin Gin Gan, Jameela Sathar, Siew Fen Lye, Letizia Foroni, Tim Aitman, Liming Liang, Michael Laffan
Journal: Blood (2015)
Ocular Flutter in the Serotonin Syndrome
Authors: Shyh-Shyong Sim, Jen-Tang Sun
Journal: New England Journal of Medicine (2016)

A 46-year-old woman was brought to the ED because of agitation. On arrival, she had a fever, tachycardia, and ocular flutter, as well as rigidity in the legs and myoclonus in the arms. Videos are available at NEJM.org.
Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab as second-line therapy for patients with stage IV acral melanoma
Authors: L. Si, Z. Chi, X. Yuan, C. Cui, X. Sheng, Y. Zhu, Y. Kong, Y. Kong, L. Shen, J. Guo
Journal: Journal of Clinical Oncology (2009)

e20010 Background: Temozolomide (TMZ) is an oral formulation of dacarbazine with improved central nervous system penetration. Sorafenib inhibits Raf kinase and vascular endothelial growth factor (VEGF) receptor. Bevacizumab is a monoclonal antibody targeted against VEGF. TMZ plus sorafenib has shown efficacy in advanced melanoma. The triple combination, chemotherapy plus the complementary inhibition of VEGF signaling, was hypothesized to have synergistic effects on acral metastatic melanoma. Methods: Eligible are refractory (previous one systemic regimen failed) acral advanced melanoma, measurable disease (RECIST). Treatment includes TMZ 200 mg/m 2 /d (days 1–5), bevacizumab 5 mg/Kg (days 1, 14) and sorafenib 400 mg/bid (days 1–28), repeated every 28days. VEGFR, PDGFR, EGFR and CD117 of tumor tissue were detected by Immunohistochemistry (IHC) assay and the DNA was abstracted and amplified by PCR assay and then sequenced to detect the mutation of C-KIT (exon11,13,17,18),B- RAF(exon11, 15) and N-RAS(exon1, 2). Progression free survival (PFS), overall survival (OS), response and toxicity were assessed. Correlation was analyzed between gene mutations, IHC results and clinical response. Results: 50 patients were planned to recruit. Till December of 2008, 11 patients all in M1c stage have been enrolled and evaluated. One patient has achieved complete response (CR) which has been lasting 5 cycles. One patient has achieved partial response (PR) with a 69% tumor reduction which has been lasting 3 cycles. One patient achieved PR with a 41% tumor reduction which has been lasting 6 cycles. 6 pts got stable disease (all tumor reduction, range: 4–21%) lasting &gt; 2 cycles (range: 3–4 cycles); and 2 PD after 1 cycle. The toxicity was moderate. It's too early to assess survival. It seemed no correlation between positive IHC results and response. It could not be decided if there is correlation between gene mutation/IHC results and response/survival. Conclusions: The triple combination (TMZ, sorafenib, and bevacizumab) regimen preliminary achieved durable clinical response especially the patients with CR or PR. The regimen is safe and well tolerated. More data will be presented in ASCO. No significant financial relationships to disclose.
The DAC Inhibitor LBH589 Is Highly Effective in Both “Therapy”-Sensitive and -Resistant Lymphomas and Enhances the Anti-Tumor Activity of Chemotherapy Agents, Monoclonal Antibodies, and Bortezomib
Authors: Ilir Maraj, Francisco J. Hernandez-Ilizaliturri, Mohammad M Chisti, Myron S. Czuczman
Journal: Blood (2008)
Two Unusual Sites of Colon Cancer Metastases and a Rare Thyroid Lymphoma
Authors: Ioannis Raftopoulos, Daniel Vanuno, Gregory Kouraklis
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.15.3576 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11481367 Two Unusual Sites of Colon Cancer Metastases and a Rare Thyroid Lymphoma Case 3. Primary T-Cell Lymphoma of the Thyroid Arising in a Background of Hashimoto's Thyroiditis Ioannis RaftopoulosxIoannis RaftopoulosSearch for articles by this author , Daniel VanunoxDaniel VanunoSearch for articles by this author , Gregory KouraklisxGregory KouraklisSearch for articles by this author Show More St Francis Hospital, Evanston, and Metropolitan Group Hospitals General Surgery Residency at Chicago, University of Illinois, Chicago, IL https://doi.org/10.1200/JCO.2001.19.15.3576 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
ATP-Induced Modulation of Norepinephrine Exocytosis in Human and Porcine Heart: Role of E-NTPDase1/CD39.
Authors: Takuji Machida, Paul M. Heerdt, Alicia C. Reid, Ulrich Schaefer, Randi B. Silver, Marinus Johan Broekman, Aaron J. Marcus, Roberto Levi
Journal: Blood (2004)
Survival after multiple traumas is associated with improved outcomes from gram-negative sepsis: Clinical and experimental evidence
Authors: Eleftherios Mandragos, Aikaterini Pistiki, Iraklis Tsangaris, Christina Routsi, Michael Paraschos, Dionyssia-Irene Droggiti, Olga Savvidou, Dimitrios Mastrokalos, Panayiotis J. Papagelopoulos, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis
Journal: Journal of Infection (2016)
A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia
Authors: Anjali Advani, Paul Elson, Eric D. Hsi, Randall Davis, Matt Kalaycio, Ronald Sobecks, Edward Copelan, Hien K. Duong, Bethany Foster, Mary Lynn Rush, Leslie Farhat, Mikkael A. Sekeres
Journal: Blood (2012)